Viral mimicry of the complement system

Journal of Biosciences

Volumn 28, Issue 3, 2003, Pages 249-264

  Bernet, John ^a   Mullick, Jayati ^a   Singh, Akhilesh K ^a   Sahu, Arvind ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

Complement system; Herpesviruses; Paramyxoviruses; Picornaviruses; Poxviruses; Retroviruses; Viral mimicry

Indexed keywords

COMPLEMENT COMPONENT C3B; VIRUS PROTEIN;

HOST-PATHOGEN INTERACTION; IMMUNE SYSTEM; MIMICRY; PATHOGEN; VIRUS;

COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; HERPES VIRUS; IMMUNE RESPONSE; MOLECULAR MIMICRY; NONHUMAN; PARAMYXOVIRUS; PHAGOCYTOSIS; PICORNAVIRUS; POXVIRUS; PROTEIN ANALYSIS; PROTEIN INTERACTION; RETROVIRUS; REVIEW; VIRUS CELL INTERACTION; VIRUS PARTICLE;

HERPESVIRIDAE; PARAMYXOVIRIDAE; PICORNAVIRIDAE; POXVIRIDAE; UNIDENTIFIED RETROVIRUS;

EID: 0037399327     PISSN: 02505991     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02970145     Document Type: Review

References (135)

1. Albrecht J C and Fleckenstein B 1992 New member of the multigene family of complement control proteins in herpesvirus saimiri; J. Virol. 66 3937-3940
2. Albrecht J C, Nicholas J, Cameron K R, Newman C, Fleckenstein B and Honess R W 1992 Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59; Virology 190 527-530
3. Alsenz J, Lambris J D, Schulz T F and Dierich M P 1984 Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38 kDa tryptic fragment of factor H; Biochem. J. 224 389-398
4. Al-Sharif W Z, Sunyer J O, Lambris J D and Smith L C 1997 Sea urchin coelomocytes specifically express a homologue of the complement component C3; J. Immunol. 160 2983-2997
5. Bartholomew R M, Esser A F and Muller-Eberhard H J 1978 Lysis of oncornaviruses by human serum. Isolation of the viral complement (C1) receptor and identification as p15E; J. Exp. Med. 147 844-853
6. Beebe D P and Cooper N R 1981 Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum; J. Immunol. 126 1562-1568
7. Beebe D P, Schreiber R D and Cooper N R 1983 Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement; J. Immunol. 130 1317-1322
8. Bergelson J M, Chan M, Solomon K R, Stjohn N F, Lin H M and Finberg R W 1994 Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses; Proc. Natl. Acad. Sci. USA 91 6245-6249
9. Bergelson J M, Mohanty J G, Crowell R L, John N F S, Lublin D M and Finberg R W 1995 Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55); J. Virol. 69 1903-1906
10. Buchholz C J, Koller D, Devaux P, Mumenthaler C, Schneider- Schaulies J, Braun W, Gerlier D and Cattaneo R 1997 Mapping of the primary binding site of measles virus to its receptor CD46; J. Biol. Chem. 272 22072-22079
11. Casasnovas J M, Larvie M and Stehle T 1999 Crystal structure of two CD46 domains reveals an extended measles virus-binding surface; EMBO J. 18 2911-2922
12. Clarkson N A, Kaufman R, Lublin D M, Ward T, Pipkin P A, Minor P D, Evans D J and Almond J W 1995 Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding; J. Virol. 69 5497-5501
13. Cooper N R 1998 Complement and viruses; in The human complement system in health and disease (eds) J E Volanakis and M M Frank (New York: Marcel Dekker) pp 393-407
14. Cooper N R and Nemerow G R 1983 Complement, viruses, and virus-infected cells; Springer Semin. Immunopathol. 6 327-347
15. Dall'Olio F, Malagolini N, Speziali V, Campadelli-Fiume G and Serafini-Cessi F 1985 Sialylated oligosaccharides O- glycosidically linked to glycoprotein C from herpes simplex virus type 1.; J. Virol. 56 127-134
16. Dempsey P W, Allison M E D, Akkaraju S, Goodnow C C and Fearon D T 1996 C3d of complement as a molecular adjuvant: bridging innate and acquired immunity; Science 271 348-350
17. Devaux P, Loveland B, Christiansen D, Milland J and Gerlier D 1996 Interactions between the ectodomains of haemagglutinin and CD46 as a primary step in measles virus entry; J. Gen. Virol. 77 1477-1481
18. Dorig R E, Marcil A, Chopra A and Richardson C D 1993 The human CD46 molecule is a receptor for measles virus (Edmonston strain); Cell 75 295-305
19. Ebenbichler C F, Thielens N M, Vornhagen R, Marschang P, Arlaud G J and Dierich M P 1991 Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41; J. Exp. Med. 174 1417-1424
20. Eisenberg R J, Ponce de Leon P, Friedman H M, Fries L F, Frank M M, Hastings J C and Cohen G H 1987 Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2; Microbial Path. 3 423-435
21. Engelstad M, Howard S T and Smith G L 1992 A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope; Virology 188 801-810
22. Ezekowitz R A, Kuhlman M, Groopman J E and Byrn R A 1989 A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus; J. Exp. Med. 169 185-196
23. Fingeroth J D, Weis J J, Tedder T F, Strominger J L, Biro P A and Fearon D T 1984 Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2; Proc. Natl. Acad. Sci. USA 81 4510-4514
24. Fodor W L, Rollins S A, Biancocaron S, Rother R P, Guilmette E R, Burton W V, Albrecht J C, Fleckenstein B and Squinto S P 1995 The complement control protein homolog of herpesvirus saimiri regulates serum complement by inhibiting C3 convertase activity; J. Virol. 69 3889-3892
25. Friedman H M, Cohen G H, Eisenberg R J, Seidel C A and Cines D B 1984 Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells; Nature (London) 309 633-635
26. Friedman H M, Wang L, Fishman N O, Lambris J D, Eisenberg R J, Cohen G H and Lubinsky J 1996 Immune evasion properties of herpes simplex virus type 1 glycoprotein gC; J. Virol. 70 4253-4260
27. Friedman H M, Wang L, Pangburn M K, Lambris J D and Lubinski J 2000 Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1; J. Immunol. 165 4528-4536
28. Fries L F, Friedman H M, Cohen G H, Eisenberg R J, Hammer C H and Frank M M 1986 Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade; J. Immunol. 137 1636-1641
29. Frink R J, Eisenberg R, Cohen G and Wagner E K 1983 Detailed analysis of the portion of the herpes simplex virus type 1 genome encoding glycoprotein C; J. Virol. 45 634-647
30. Goebel S J, Johnson G P, Perkus M E, Davis S W, Winslow J P and Paoletti E 1990 The complete DNA sequence of vaccinia virus; Virology 179 247-263
31. Gordon D L, Kaufman R M, Blackmore T K, Kwong J and Lublin D M 1995 Identification of complement regulatory domains in human factor H; J. Immunol. 155 348-356
32. Henderson C E, Bromek K, Mullin N P, Smith B O, Uhrin D and Barlow P N 2001 Solution structure and dynamics of the central CCP module pair of a poxvirus complement control protein; J. Mol. Biol. 307 323-339
33. Hidaka Y, Sakai Y, Toh Y and Mori R 1991 Glycoprotein C of herpes simplex virus type 1 is essential for the virus to evade antibody-independent complement-mediated virus inactivation and lysis of virus-infected cells; J. Gen. Virol. 72 915-921
34. Hidaka Y, Sakuma S, Kumano Y, Minagawa H and Mori R 1990 Characterization of glycoprotein C-negative mutants of herpes simplex virus type 1 isolated from a patient with keratitis; Arch. Virol. 113 195-207
35. Hirsch R L, Winkelstein J A and Griffin D E 1980 The role of complement in viral infections. III. Activation of the classical and alternative complement pathways by Sindbis virus; J. Immunol. 124 2507-2510
36. Hung S L, Peng C, Kostavasili I, Friedman H M, Lambris J D, Eisenberg R J and Cohen G H 1994 The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway; Virology 203 299-312
37. Hung S L, Srinivasan S, Friedman H M, Eisenberg R J and Cohen G H 1992 Structural basis of C3b binding by glycoprotein-C of herpes simplex virus; J. Virol. 66 4013-4027
38. Isaacs S N, Kotwal G J and Moss B 1992a Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence; Proc. Natl. Acad. Sci. USA 89 628-632
39. Isaacs S N, Wolffe E J, Payne L G and Moss B 1992b Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope; J. Virol. 66 7217-7224
40. Ishii Y, Shimomura H, Itoh M, Miyake M, Ikeda F, Miyaike J, Fujioka S, Iwasaki Y, Tsuji H and Tsuji T 2001 Cold activation of serum complement in patients with chronic hepatitis C: study on activating pathway and involvement of IgG; Acta Med. Okayama 55 229-235
41. Iwata K, Seya T, Yanagi Y, Pesando J M, Johnson P M, Okabe M, Ueda S, Ariga H and Nagasawa S 1995 Diversity of sites for measles virus binding and for inactivation of complement C3b and C4b on membrane cofactor protein CD46; J. Biol. Chem. 270 15148-15152
42. Ji X, Azumi K, Sasaki M and Nonaka M 1997 Ancient origin of the complement lectin pathway revealed by molecular cloning of mannan binding protein-associated serine protease from a urochordate, the Japanese ascidian, Halocynthia roretzi 49; Proc. Natl. Acad. Sci. USA 94 6340-6345
43. Johnson D C and Spear P G 1983 O-linked oligosaccharides are acquired by herpes simplex virus glycoproteins in the Golgi apparatus; Cell 32 987-997
44. Kelkar S D and Gogate S S 1987 Macrophage-virus interaction during Con A-induced protection against Japanese encephalitis virus in infant mice; Acta Virol. 31 103-108
45. Kim Y U, Carroll M C, Isenman D E, Nonaka M, Pramoonjago P, Takeda J, Inoue K and Kinoshita T 1992 Covalent binding of C3b to C4b within the classical complement pathway C5 convertase: Determination of amino acid residues involved in ester linkage formation; J. Biol. Chem. 267 4171-4176
46. Kinoshita T, Takata Y, Kozono H, Takeda J, Hong K and Inoue K 1988 C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme; J. Immunol. 141 3895-3901
47. Klickstein L B, Bartow T J, Miletic V, Rabson L D, Smith J A and Fearon D T 1988 Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis; J. Exp. Med. 168 1699-1717
48. Kostavasil I, Sahu A, Friedman H M, Eisenberg R J, Cohen G H and Lambris J D 1997 Mechanism of complement inactivation by glycoprotein C of herpes simplex virus; J. Immunol. 158 1763-1771
49. Kotwal G J, Isaacs S N, Mckenzie R, Frank M M and Moss B 1990 Inhibition of the complement cascade by the major secretory protein of vaccinia virus; Science 250 827-830
50. Kotwal G J and Moss B 1988 Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins; Nature (London) 335 176-178
51. Krych M, Hourcade D and Atkinson J P 1991 Sites within the complement C3b C4b receptor important for the specificity of ligand binding; Proc. Natl. Acad. Sci. USA 88 4353-4357
52. Lambris J D, Ganu V S, Hirani S and Müller-Eberhard H J 1985 Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement; Proc. Natl. Acad. Sci. USA 82 4235-4239
53. Lambris J D, Sahu A and Wetsel R 1998 The chemistry and biology of C3,C4, and C5; in The human complement system in health and disease (eds) J E Volanakis and M Frank (New York: Marcel Dekker) pp 83-118
54. Lea S M, Powell R M, Mckee T, Evans D J, Brown D, Stuart D I and van der Merwe P A 1998 Determination of the affinity and kinetic constants for the interaction between the human virus echovirus 11 and its cellular receptor, CD55; J. Biol. Chem. 273 30443-30447
55. Levashina E A, Moita L F, Blandin S, Vriend G, Lagueux M and Kafatos F C 2001 Conserved role of a complement-like protein in phagocytosis revealed by dsRNA knockout in cultured cells of the mosquito, Anopheles gambiae; Cell 104 709-718
56. Lowell C A, Klickstein L B, Carter R H, Mitchell J A, Fearon D T and Ahearn J M 1989 Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2; J. Exp. Med. 170 1931-1946
57. Lubinski J, Wang L, Mastellos D, Sahu A, Lambris J D and Friedman H M 1999 In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC; J. Exp. Med. 190 1637-1646
58. Maisner A, Alvarez J, Liszewski M K, Atkinson D J, Atkinson J P and Herrler G 1996 The N-glycan of the SCR 2 region is essential for membrane cofactor protein (CD46) to function as a measles virus receptor; J. Virol. 70 4973-4977
59. Manchester M, Gairin J E, Patterson J B, Alvarez J, Liszewski M K, Eto D S, Atkinson J P and Oldstone M B 1997 Measles virus recognizes its receptor, CD46, via two distinct binding domains within SCR1-2; Virology 233 174-184
60. Manchester M, Liszewski M K, Atkinson J P and Oldstone M B 1994 Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus; Proc. Natl. Acad. Sci. USA 91 2161-2165
61. Manchester M and Rall G F 2001 Model Systems: transgenic mouse models for measles pathogenesis; Trends Microbiol. 9 19-23
62. Manchester M, Valsamakis A, Kaufman R, Liszewski M K, Alvarez J, Atkinson J P, Lublin D M and Oldstone M B A 1995 Measles virus and C3 binding sites are distinct on membrane cofactor protein (CD46); Proc. Natl. Acad. Sci. USA 92 2303-2307
63. Marschang P, Sodroski J, Wurzner R and Dierich M P 1995 Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement; Eur. J. Immunol. 25 285-290
64. Martinezpomares L, Thompson J P and Moyer R W 1995 Mapping and investigation of the role in pathogenesis of the major unique secreted 35-kDa protein of rabbitpox virus; Virology 206 591-600
65. Mckenzie R, Kotwal G J, Moss B, Hammer C H and Frank M M 1992 Regulation of complement activity by vaccinia virus complement-control protein; J. Infect. Dis. 166 1245-1250
66. McNearney T A, Odell C, Holers V M, Spear P G and Atkinson J P 1987 Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity; J. Exp. Med. 166 1525-1535
67. McSharry J J, Pickering R J and Caliguiri L A 1981 Activation of the alternative complement pathway by enveloped viruses containing limited amounts of sialic acid; Virology 114 507-515
68. Miller C G, Shchelkunov S N and Kotwal G J 1997 The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein; Virology 229 126-133
69. Mold C, Bradt B M, Nemerow G R and Cooper N R 1988a Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350; J. Immunol. 140 3867-3874
70. Mold C, Bradt B M, Nemerow G R and Cooper N R 1988b Epstein-Barr virus regulates activation and processing of the third component of complement; J. Exp. Med. 168 949-969
71. Molina H, Brenner C, Jacobi S, Gorka J, Carel J C, Kinoshita T and Holers V M 1991 Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction; J. Biol. Chem. 266 12173-12179
72. Montefiori D C, Cornell R J, Zhou J Y, Zhou J T, Hirsch V M and Johnson P R 1994 Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection; Virology 205 82-92
73. Morgan B P 1999 Regulation of the complement membrane attack pathway; Crit. Rev. Immunol. 19 173-198
74. Murthy K H, Smith S A, Ganesh V K, Judge K W, Mullin N, Barlow P N, Ogata C M and Kotwal G J 2001 Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans; Cell 104 301-311
75. Naniche D, Variorkrishnan G, Cervoni F, Wild T F, Rossi B, Rabourdincombe C and Gerlier D 1993 Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus; J. Virol. 67 6025-6032
76. Nemerow G R and Cooper N R 1981 Isolation of Epstein Barr-virus and studies of its neutralization by human IgG and complement; J. Immunol. 127 272-278
77. Nemerow G R, Houghten R A, Moore M D and Cooper N R 1989 Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2); Cell 56 369-377
78. Nemerow G R, Mold C, Schwend V K, Tollefson V and Cooper N R 1987 Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d; J. Virol. 61 1416-1420
79. Nonaka M, Azumi K, Ji X, Namikawa-Yamada C, Sasaki M, Saiga H, Dodds A W, Sekine H, Homma M K, Matsushita M, Endo Y and Fujita T 1999 Opsonic complement component C3 in the solitary ascidian, Halocynthia roretzi; J. Immunol. 162 387-391
80. Nussbaum O, Broder C C, Moss B, Stern L B, Rozenblatt S and Berger E A 1995 Functional and structural interactions between measles virus hemagglutinin and CD46; J. Virol. 69 3341-3349
81. Oldstone M B, Cooper N R and Larson D L 1974 Formation and biologic role of polyoma virus-antibody complexes. A critical role for complement; J. Exp. Med. 140 549-565
82. Pinter C, Siccardi A G, Longhi R and Clivio A 1995a Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120; AIDS Res. Hum. Retroviruses 11 577-588
83. Pinter C, Siccardi A G, Lopalco L, Longhi R and Clivio A 1995b HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology; AIDS Res. Hum. Retroviruses 11 971-980
84. Powell R M, Ward T, Evans D J and Almond J W 1997 Interaction between echovirus 7 and its receptor, decay-accelerating factor (CD55): evidence for a secondary cellular factor in A-particle formation; J. Virol. 71 9306-9312
85. Prodeus A P, Goerg S, Shen L M, Pozdnyakova O O, Chu L, Alicot E M, Goodnow C C and Carroll M C 1998 A critical role for complement in maintenance of self-tolerance; Immunity 9 721-731
86. Robinson W E Jr, Montefiori D C and Mitchell W M 1988 Antibody-dependent enhancement of human immunodeficiency virus type 1 infection; Lancet 1 790-794
87. Rosengard A M and Ahearn J M 1998 Creation and functional characterization of spice, the small pox inhibitor of complement enzymes; Mol. Immunol. 35 397
88. Rosengard A M, Alonso L C, Korb L C, Baldwin W M III, Sanfilippo F, Turka L A and Ahearn J M 1999 Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP); Mol. Immunol. 36 685-697
89. Rother R P, Rollins S A, Fodor W L, Albrecht J C, Setter E, Fleckenstein B and Squinto S P 1994 Inhibition of complement-mediated cytolysis by the terminal complement inhibitor of herpesvirus saimiri; J. Virol. 68 730-737
90. Russo J J, Bohenzky R A, Chien M C, Chen J, Yan M, Maddalena D, Parry J P, Peruzzi D, Edelman I S, Chang Y and Moore P S 1996 Nucleotide sequence of the Kaposi sarcomaassociated herpesvirus (HHV8); Proc. Natl. Acad. Sci. USA 93 14862-14867
91. Rux A H, Moore W T, Lambris J D, Abrams W R, Peng C, Friedman H M, Cohen G H and Eisenberg R J 1996 Disulfide bond structure determination and biochemical analysis of glycoprotein C from herpes simplex virus; J. Virol. 70 5455-5465
92. 1 inactivates the alternative complement pathway; J. Immunol. 160 5596-5604
93. Sahu A, Kozel T R and Pangburn M K 1994 Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation; Biochem. J. 302 429-436
94. Sahu A and Lambris J D 2000 Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics; Immunopharmacology 49 133-148
95. Sahu A and Lambris J D 2001 Structure and biology of complement protein C3, a connecting link between innate and acquired immunity; Immunol. Rev. 180 35-48
96. Sahu A, Morikis D and Lambris J D 2000 Complement inhibitors targeting C3, C4, and C5; in Therapeutic interventions in the complement system (eds) J D Lambris and V M Holers (Totowa: Humana Press) pp 75-112
97. Sahu A and Pangburn M K 1993 Identification of multiple sites of interaction between heparin and the complement system; Mol. Immunol. 30 679-684
98. Sahu A and Pangburn M K 1994 Covalent attachment of human complement C3 to IgG: Identification of the amino acid residue involved in ester linkage formation; J. Biol. Chem. 269 28997-29002
99. Sahu A and Pangburn M K 1995 Tyrosine is a potential site for covalent attachment of activated commplement component C3; Mol. Immunol. 32 711-716
100. Sahu A, Sunyer J O, Moore W T, Sarrias M R, Soulika A M and Lambris J D 1998a Structure, functions, and evolution of the third complement component and viral molecular mimicry; Immunol. Res. 17 109-121
101. Saifuddin M, Hart M L, Gewurz H, Zhang Y and Spear G T 2000 Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1; J. Gen. Virol. 81 949-955
102. Saifuddin M, Parker C J, Peeples M E, Gorny M K, Zolla-Pazner S, Ghassemi M, Rooney I A, Atkinson J P and Spear G T 1995 Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1; J. Exp. Med. 182 501-509
103. Santoro F, Kennedy P E, Locatelli G, Malnati M S, Berger E A and Lusso P 1999 CD46 is a cellular receptor for human herpesvirus 6; Cell 99 817-827
104. Sarrias M R, Franchini S, Canziani G, Argyropoulos E, Moore W T, Sahu A and Lambris J D 2001 Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220; J. Immunol. 167 1490-1499
105. Schmitz J, Zimmer J P, Kluxen B, Aries S, Bogel M, Gigli I and Schmitz H 1995 Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59; J. Clin. Invest. 96 1520-1526
106. Schwarting R, Stein H and Wang C Y 1985 The monoclonal antibodies αS-HCL 1 (αLeu-14) and αS-HCL 3 (αLeu-M5) allow the diagnosis of hairy cell leukemia; Blood 65 974-983
107. Seidel-Dugan C, Ponce de Leon M, Friedman H M, Eisenberg R J and Cohen G H 1990 Identification of C3b-binding regions on herpes simplex virus type 2 glycoprotein C; J. Virol. 64 1897-1906
108. Sekine H, Kenjo A, Azumi K, Ohi G, Takahashi M, Kasukawa R, Ichikawa N, Nakata M, Mizuochi T, Matsushita M, Endo Y and Fujita T 2001 An ancient lectin-dependent complement system in an ascidian: novel lectin isolated from the plasma of the solitary ascidian, Halocynthia roretzi; J. Immunol. 167 4504-4510
109. Shafren D R, Bates R C, Agrez M V, Herd R L, Burns G F and Barry R D 1995 Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment; J. Virol. 69 3873-3877
110. Shafren D R, Dorahy D J, Ingham R A, Burns G F and Barry R D 1997a Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry; J. Virol. 71 4736-4743
111. Shafren D R, Williams D T and Barry R D 1997b A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells; J. Virol. 71 9844-9848
112. Sharma A K and Pangburn M K 1996 Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis; Proc. Natl. Acad. Sci. USA 93 10996-11001
113. Spear G T, Hart M, Olinger G G, Hashemi F B and Saifuddin M 2001 The role of the complement system in virus infections; Curr. Top. Microbiol. Immunol. 260 229-245
114. Spear G T, Lurain N S, Parker C J, Ghassemi M, Payne G H and Saifuddin M 1995 Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV); J. Immunol. 155 4376-4381
115. Spear G T, Sullivan B L, Takefman D M, Landay A L and Lint T F 1991 Human immunodeficiency virus (HIV)-infected cells and free virus directly activate the classical complement pathway in rabbit, mouse and guinea-pig sera; activation results in virus neutralization by virolysis; Immunology 73 377-382
116. Spear P G 1985 Antigenic structure of herpes simplex viruses; in Immunochemistry of viruses. The basis for serodiagnosis and vaccines (eds) M V H van Regenmortel and A R Neurath (Amsterdam: Elsevier Science Publishers) pp 425-446
117. Stoiber H, Clivio A and Dierich M P 1997 Role of complement in HIV infection; Annu. Rev. Immunol. 15 649-674
118. Stoiber H, Kacani L, Speth C, Wurzner R and Dierich M P 2001 The supportive role of complement in HIV pathogenesis; Immunol. Rev. 180 168-176
119. Stoiber H, Pinter C, Siccardi A G, Clivio A and Dierich M P 1996 Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55); J. Exp. Med. 183 307-310
120. Stoiber H, Schneider R, Janatova J and Dierich M P 1995 Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1; Immunobiology 193 98-113
121. Sullivan B L, Takefman D M and Spear G T 1998 Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism; Virology 248 173-181
122. Sun X, Funk C D, Deng C, Sahu A, Lambris J D and Song W C 1999 Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting; Proc. Natl. Acad. Sci. USA 96 628-633
123. Susal C, Kirschfink M, Kropelin M, Daniel V and Opelz G 1994 Complement activation by recombinant HIV-1 glycoprotein gp120; J. Immunol. 152 6028-6034
124. Swain M A, Peet R W and Galloway D A 1985 Characterization of the gene encoding herpes simplex virus type 2 glycoprotein C and comparison with the type 1 counterpart; J. Virol. 53 561-569
125. Takahashi-Nishimaki F, Funahashi S, Miki K, Hashizume S and Sugimoto M 1991 Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins; Virology 181 158-164
126. Tanner J, Weis J, Fearon D, Whang Y and Kieff E 1987 Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis; Cell 50 203-213
127. Tanner J, Whang Y, Sample J, Sears A and Kieff E 1988 Soluble gp350/220 and deletion mutant glycoprotein block Epstein-Barr virus adsorption to lymphocytes; J. Virol. 62 4452-4464
128. Van Strijp J A, Miltenburg L A, van der Tol M E, Van Kessel K P, Fluit A C and Verhoef J 1990 Degradation of herpes simplex virions by human polymorphonuclear leukocytes and monocytes; J. Gen. Virol. 71 1205-1209
129. Vanderplasschen A, Mathew E, Hollinshead M, Sim R B and Smith G L 1998 Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope; Proc. Natl. Acad. Sci. USA 95 7544-7549
130. Virgin H W, Latreille P, Wamsley P, Hallsworth K, Weck K E, DalCanto A J and Speck S H 1997 Complete sequence and genomic analysis of murine gammaherpesvirus 68; J. Virol. 71 5894-5904
131. Wakimoto H, Ikeda K, Abe T, Ichikawa T, Hochberg F H, Ezekowitz R A, Pasternack M S and Chiocca E A 2002 The complement response against an oncolytic virus is species-specific in its activation pathways; Mol. Ther. 5 275-282
132. Wedgewood R J, Ginsberg H S and Pillemer H 1956 The properdin system and immunity. VI. The inactivation of New-castle disease virus by the properdin system; J. Exp. Med. 104 707-725
133. Welsh R M Jr, Lampert P W, Burner P A and Oldstone M B 1976 Antibody-complement interactions with purified lymphocytic choriomeningitis virus; Virology 73 59-71
134. Wiles A P, Shaw G, Bright J, Perczel A, Campbell I D and Barlow P N 1997 NMR studies of a viral protein that mimics the regulators of complement activation; J. Mol. Biol. 272 253-265
135. Zezulak K M and Spear P G 1984 Mapping of the structural gene for the herpes simplex virus type 2 counterpart of herpes simplex virus type 1 glycoprotein C and identification of a type 2 mutant which does not express this glycoprotein; J. Virol. 49 741-747